World News

Federal regulators are revising how testosterone replacement therapy is presented to physicians and patients, marking one of the most significant shifts in U.S. hormone-treatment policy in more than a decade.

In June 2026, the Department of Health and Human Services announced that the Food and Drug Administration had requested updates to prescribing information for testosterone products. The proposed revisions would remove the label limitation stating that testosterone therapy’s safety and effectiveness have not been established in men with age-related hypogonadism. They would also revise warnings involving prostate cancer and benign prostatic hyperplasia, or enlarged prostate.

The agency said its review found that clinical and epidemiological evidence has not demonstrated an increased prostate-cancer risk among appropriately treated men. Under the requested language, testosterone therapy would be contraindicated specifically in men with metastatic prostate cancer, while physicians would still be advised to evaluate prostate risk before treatment and continue appropriate monitoring.

The 2026 action follows an FDA labeling change announced in February 2025. Based on the TRAVERSE cardiovascular-safety trial involving more than 5,200 men, regulators removed language from the boxed warning suggesting that testosterone increased the risk of cardiovascular events. In the study, major cardiovascular events occurred in 7.0% of testosterone recipients and 7.3% of placebo recipients.

That did not eliminate every cardiovascular concern. FDA-required ambulatory blood-pressure studies found that testosterone products can increase blood pressure. The agency consequently required product-specific blood-pressure information and new hypertension warnings for formulations that did not already carry them.

Interest in hormone evaluation has been growing in clinics.

“We've definitely seen a greater influx over the past several years of patients that are more educated regarding the value to hormone optimization, specifically in regards to testosterone. I think regulatory changes and the general acceptance by the overall medical community due to newer research has helped increase the popularity of these treatments,” said Tim Bruce, founder of NovaGenix Health & Wellness in Jupiter, Florida.

The evolving labels do not mean testosterone has become an unrestricted wellness product. Testosterone remains a Schedule III controlled substance under federal law and requires a prescription. FDA information continues to distinguish medically supervised treatment from nonmedical bodybuilding, performance enhancement or unsupervised “anti-aging” use.

Patients still need a clinical evaluation. Symptoms such as fatigue, reduced sexual desire, loss of muscle mass and mood changes are not specific to testosterone deficiency. Diagnosis generally requires a medical history, physical assessment and timed laboratory testing rather than symptoms alone.

Monitoring remains central to responsible treatment. Clinicians may evaluate testosterone levels, blood pressure, hematocrit, prostate-specific antigen and other health markers based on the patient’s age, history and treatment plan. Testosterone can increase red-blood-cell production, affect fertility and require adjustment when laboratory values move outside acceptable ranges.

The regulatory direction is more accepting of testosterone therapy when supported by evidence, but it is not an endorsement of indiscriminate prescribing. The shift is toward clearer risk communication and individualized medical decisions grounded in symptoms, laboratory findings and careful physician oversight.